IVF Showcases Its Potential as an International Standard Fertility Treatment Center and Announces IPO Price at THB 3.10 per Share, Open for Subscription from November 29–December 3, 2024
Bangkok, November 28, 2024 - Inspire IVF Public Company Limited (“IVF”) is preparing to offer up to 130 million newly issued ordinary shares through its initial public offering (IPO), representing no more than 29.55% of the company’s total issued and paid-up shares. The fundraising aims to support domestic and international branch expansion, as well as the development of preventive and regenerative healthcare services.
With continued growth opportunities in the global fertility treatment industry, IVF is moving forward with its vision of becoming “a leading fertility treatment center with international standards in Thailand and Asia.” The company has set the IPO offering price at THB 3.10 per share, representing a total offering value of THB 403 million. Investors can subscribe for shares from November 29 to December 3, 2024, with the company expected to begin trading on the Market for Alternative Investment (mai) on December 11, 2024.
Ms. Kesinee Kuldilok, Chief Executive Officer of Inspire IVF Public Company Limited (“IVF”), stated that according to a report on the global fertility industry by Allied Market Research, the global fertility tourism market is projected to reach USD 33.6 billion by 2027, representing a compound annual growth rate (CAGR) of 14.2%. The Asia-Pacific region is expected to become the largest market, with an estimated value of USD 5.62 billion and a CAGR of 14.7% during 2019-2027.
Thailand is considered a key destination for fertility tourism in Asia, supported by government initiatives to position Thailand as a medical hub, strong healthcare capabilities, and accessible treatment costs.
Ms. Kesinee further explained that throughout more than six years of operating as an international-standard fertility treatment center, IVF has achieved a three-year success rate (2021–2023) of 70–76%, exceeding industry averages. This achievement is supported by international service standards, experienced physicians and scientists, advanced assisted reproductive technologies, and continuous investment in cutting-edge medical innovations.
These technologies include EmbryoScope Plus, an embryo incubator equipped with real-time monitoring and AI-assisted embryo quality assessment, as well as PGT-A/PGT-SR genetic screening using SNP Array technology from Illumina, USA, which enables accurate detection of genetic abnormalities. These innovations help reduce treatment time, improve convenience for patients, and enhance pregnancy success opportunities.
Through strong service quality and patient experiences, IVF has developed a broad word-of-mouth reputation and expanded its international customer base, with more than 80% of clients coming from overseas markets such as India, China, Vietnam, and Australia.
The IPO proceeds will be used to expand domestic and international branches (New Market) and enhance preventive and regenerative medicine services (New Service), supporting IVF’s goal of becoming a leading fertility treatment center in Thailand and Asia while preparing for the future growth of fertility tourism.
Mr. Worachat Thuaycharoen, Managing Director of Finnex Advisory Company Limited, the company’s financial advisor, added that IVF represents an attractive growth stock opportunity with strong potential for sustainable returns. The company has demonstrated significant revenue growth over the past three years, increasing from THB 11.24 million in 2021 to THB 63.31 million in 2022 and THB 121.55 million in 2023, primarily driven by fertility treatment services.
For the first nine months of 2024, IVF generated service revenue of THB 83.28 million, consisting of THB 76.61 million (92%) from fertility treatment services and THB 6.67 million (8%) from preventive and regenerative healthcare services. The company recorded a return on equity (ROE) of 35.1% and a return on assets (ROA) of 19.9%.
IVF will offer up to 130,000,000 IPO shares, representing 29.55% of total issued and paid-up shares, at an offering price of THB 3.10 per share, with a total offering value of up to THB 403 million. The subscription period will be open from November 29, 2024, at 8:30 AM until December 3, 2024, at 4:30 PM through the appointed securities distributors, including:
- Kingsford Securities Public Company Limited
- Krungthai XSpring Securities Company Limited
- DAOL Securities (Thailand) Public Company Limited
- Beyond Securities Public Company Limited
- Liberator Securities Company Limited
- ASL Securities Company Limited
- AIRA Securities Public Company Limited
Mr. Worachat expressed confidence that IVF is ready to advance toward becoming a leading international-standard fertility treatment center representing Thailand on the global stage under the concept “Simplicity in Every Step”, making every dream of parenthood easier and achievable.
- Expert medical and scientific teams
- Advanced reproductive technologies
- International quality management systems
- Comprehensive and personalized patient care
- Strong strategic partnerships
With a reported success rate of up to 76%, higher than Thailand’s average pregnancy success rate according to the Department of Health Service Support (DHSS), IVF is expected to be listed on the mai Exchange under the Service Industry category in the near future.
For more information about Inspire IVF Public Company Limited (“IVF”), visit the official website: https://www.inspireivf.com or Facebook page: https://www.facebook.com/inspireivfthailand or contact us at 063-531-8666 and 02-251-8666
